Publicaciones científicas

Búsqueda avanzada

Mieloma múltiple y nuevos fármacos

Año: 2012
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
  Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J.
  Blood 120: 1589-1596. FI: 9,898 (Q1) (D1)
  PubMed
- The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation
  Caballero-Velázquez T; Sánchez-Abarca LI; Gutierrez-Cosio S; Blanco B; Calderon C; Herrero C; Carrancio S; Serrano C; del Cañizo C; San Miguel JF; Pérez-Simón JA.
  Haematologica-The Hematology Journal. 97: 1329-1337. FI: 6,424 (Q1) (D1)
  PubMed
- Transcriptomic rationale for the synergy observed with dasatinib plus bortezomib plus dexamethasone in multiple myeloma
  de Queiroz Crusoe, Edvan; Maiso, Patricia; Fernandez-Lazaro, Diego; San-Segundo, Laura; Garayoa, Mercedes; Garcia-Gomez, Antonio; Gutierrez, Norma C.; Delgado, Manuel; Colado, Enrique; Martin-Sanchez, Jesus; Lee, Francis Y.; Ocio, Enrique M..
  Annals Of Hematology. 91: 257-269. FI: 2,615 (Q2) (D5)
  PubMed
Año: 2011
- An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation
  Ivan Spicka; María Victoria Mateos ; K. Redman; M. A. Dimopoulos; P. G. Richardson
  Immunotherapy 3: 1033-1040. FI: 0,542(Q4)
- BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
  Giuseppe Visani; Lara Malerba; Pietro Maria Stefani; Saveria Capria; Piero Galieni; Francesco Gaudio; Giorgina Specchia; Giovanna Meloni; Filippo Gherlinzoni; Claudio Giardini; Sadia Falcioni; Francesca Cuberli; Marco Gobbi; Barbara Sarina; Armando Santoro; Felicetto Ferrara; Marco Rocchi; Enrique M Ocio San Miguel; María Dolores Caballero ; Alessandro Isidori
  Blood 118: 3419-3425. FI: 10,558(Q1)
- Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients
  Bruno David Lourenço Paiva; Norma Carmen Gutiérrez Gutiérrez; Xi Chen Chen; María Belén Vidriales Vicente; Maria-Angeles Montalban; Laura Rosinol; Albert Oriol; Joaquin Martinez-Lopez; María Victoria Mateos ; Lucía López Corral; MARÍA ELENA DIAZ Rodríguez; José Juan Pérez Morán; Elena Fernandez-Redondo; Felipe de Arriba; Luis Palomera; Enrique Bengoechea; Maria Jose Terol; Raquel de Paz; Alejandro Martín García Sancho; Jose Hernandez; JOSE ALBERTO ORFAO DE MATOS CORREIA E VALE; Juan Jose Lahuerta; Joan Blade; Atanasio Pandiella ; Jesús Fernando San Miguel Izquierdo
  Blood 118: 1682-1683. FI: 10,558(Q1)
- Bone Marrow Mesenchymal Stem Cells for Improving Hematopoietic Function: An In Vitro and In Vivo Model. Part 2: Effect on Bone Marrow Microenvironment
  María Soraya Carrancio Anton; Belén Blanco Durango; Carlos Romo Gonzalo; Sandra Muntión Olave; Natalia Lopez-Holgado; Juan Francisco Blanco Blanco; JESÚS MARÍA GARCÍA BRIÑÓN; Jesús Fernando San Miguel Izquierdo; FERMIN Martín Sánchez GUIJO; Consuelo Del Cañizo Fernández Roldán
  Plos One 6: -0. FI: 4,411(Q1)
- Can multiple myeloma become a curable disease?
  Jesús Fernando San Miguel Izquierdo; María Victoria Mateos
  Haematologica-The Hematology Journal 96: 1246-1248. FI: 6,532(Q1)
- CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features
  Martin Schmidt-Hieber; Martín Pérez Andrés; Bruno David Lourenço Paiva; Juan Alejandro Flores Montero; José Juan Pérez Morán; Norma Carmen Gutiérrez Gutiérrez; María Belén Vidriales Vicente; SERGIO MATARRAZ SUÓN; Jesús Fernando San Miguel Izquierdo; JOSE ALBERTO ORFAO DE MATOS CORREIA E VALE
  Haematologica-The Hematology Journal 96: 328-332. FI: 6,532(Q1)
- Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
  Paul Richardson; Rudolf Schlag; Nuriet Khuageva; Meletios Dimopoulos; Ofer Shpilberg; Martin Kropff; Marie-Christiane Vekemans; Maria Teresa Petrucci; Viktor Rossiev; Jian Hou; Tadeusz Robak; María Victoria Mateos ; Kenneth Anderson; Dixie-Lee Esseltine; Andrew Cakana; Kevin Liu; William Deraedt; Helgi van de Velde; Jesús Fernando San Miguel Izquierdo
  British Journal Of Haematology 153: 212-221. FI: 4,942(Q1)

204 resultados

Páginas: << < 2 3 4 5 6 > >>

NoticiasNoticias
Zona del InvestigadorZona del Investigador